A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

October 7, 2024

Study Completion Date

December 7, 2026

Conditions
Bladder Cancer
Interventions
DRUG

IAP0971

Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times

COMBINATION_PRODUCT

IAP0971+BCG

Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder perfusion,Maintain at months 3, 6, 12, 18, and 24Perfusion, once a week, three times in a row.

COMBINATION_PRODUCT

IAP0971+BCG

Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder irrigationNote, progress at months 3, 6, 12, 18, and 24Perform maintenance perfusion once a week, three times in a row.

All Listed Sponsors
lead

SUNHO(China)BioPharmaceutical CO., Ltd.

INDUSTRY

NCT06255964 - A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter